JP2023110094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023110094A5 JP2023110094A5 JP2023096315A JP2023096315A JP2023110094A5 JP 2023110094 A5 JP2023110094 A5 JP 2023110094A5 JP 2023096315 A JP2023096315 A JP 2023096315A JP 2023096315 A JP2023096315 A JP 2023096315A JP 2023110094 A5 JP2023110094 A5 JP 2023110094A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- lymphoma
- leukemia
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 230000004850 protein–protein interaction Effects 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000000516 mast-cell leukemia Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024111017A JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635834P | 2018-02-27 | 2018-02-27 | |
| US62/635,834 | 2018-02-27 | ||
| JP2020544852A JP7317032B2 (ja) | 2018-02-27 | 2019-02-27 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
| PCT/US2019/019856 WO2019169001A1 (en) | 2018-02-27 | 2019-02-27 | Chromene derivatives as inhibitors of tcr-nck interaction |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544852A Division JP7317032B2 (ja) | 2018-02-27 | 2019-02-27 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111017A Division JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023110094A JP2023110094A (ja) | 2023-08-08 |
| JP2023110094A5 true JP2023110094A5 (https=) | 2023-09-11 |
| JP7521070B2 JP7521070B2 (ja) | 2024-07-23 |
Family
ID=65724589
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544852A Active JP7317032B2 (ja) | 2018-02-27 | 2019-02-27 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
| JP2023096315A Active JP7521070B2 (ja) | 2018-02-27 | 2023-06-12 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
| JP2024111017A Pending JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544852A Active JP7317032B2 (ja) | 2018-02-27 | 2019-02-27 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111017A Pending JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10696663B2 (https=) |
| EP (1) | EP3759086A1 (https=) |
| JP (3) | JP7317032B2 (https=) |
| KR (2) | KR20260028873A (https=) |
| CN (2) | CN117304157A (https=) |
| AU (2) | AU2019229258B2 (https=) |
| BR (1) | BR112020017386A2 (https=) |
| CA (1) | CA3091202A1 (https=) |
| CO (1) | CO2020010537A2 (https=) |
| EA (1) | EA202091742A1 (https=) |
| IL (2) | IL301120B2 (https=) |
| MX (2) | MX2020008814A (https=) |
| PH (1) | PH12020500638A1 (https=) |
| SG (1) | SG11202008067QA (https=) |
| WO (1) | WO2019169001A1 (https=) |
| ZA (1) | ZA202310843B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260028873A (ko) | 2018-02-27 | 2026-03-04 | 아텍스 바이오파마 인코포레이티드 | Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체 |
| WO2025137442A1 (en) * | 2023-12-22 | 2025-06-26 | Artax Biopharma Inc. | SOLID AND SALT FORMS OF TCR-NcK MODULATORS AND USES THEREOF |
| WO2025255109A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a chromene derivative tcr inhibitor and a pde4 inhibitor |
| WO2025255091A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a chromene derivative tcr inhibitor and a jak inhibitor |
| WO2025255093A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a car-t therapy and a chromene derivative tcr inhibitor |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| FR2772761B1 (fr) * | 1997-12-23 | 2000-05-26 | Lipha | Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant |
| TR200401209T4 (tr) | 1999-11-05 | 2004-07-21 | Cytovia, Inc. | Kaspazların aktivatörleri ve apoptoz endüserleri olarak yer değiştiren 4H-kromen ve analogları ile bunların kullanımı |
| EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
| WO2002008217A2 (en) | 2000-07-21 | 2002-01-31 | Chugai Seiyaku Kabushiki Kaisha | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| WO2002092076A1 (en) | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
| WO2003016270A2 (en) * | 2001-08-11 | 2003-02-27 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
| WO2003062272A1 (es) | 2002-01-24 | 2003-07-31 | Consejo Superior De Investigaciones Científicas | Nueva estrategia moduladora de la activacion de los linfocitos t basada en la regulación de la interaccion cd3e- nck. |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7476741B2 (en) | 2002-05-16 | 2009-01-13 | Cytovia, Inc. | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| CN1832939B (zh) | 2003-05-30 | 2010-04-28 | 杰明X医药品加拿大公司 | 用于治疗癌症或病毒病的三杂环化合物、组合物和方法 |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| BRPI0617162B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| GB0607389D0 (en) | 2006-04-12 | 2006-05-24 | Novartis Ag | Organic compounds |
| MX2008013578A (es) | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US20110207729A1 (en) * | 2007-08-10 | 2011-08-25 | Astellas Pharma Inc. | Bicyclic acylguanidine derivative |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| ES2331451B1 (es) | 2008-06-30 | 2010-10-21 | Consejo Superior De Investigaciones Cientificas (Csic) | Inmunosupresor basado en la interrupcion de la interaccion tcr-nck. |
| US8759390B2 (en) | 2008-07-16 | 2014-06-24 | Bristol-Myers Squibb Company | Chromene modulators of chemokine receptor activity |
| ES2334318B2 (es) | 2008-09-05 | 2011-11-28 | Universidad Politécnica de Madrid | Sistema de deteccion optica para bio-ensayos de alta sensibilidad sinmarcado. |
| US8193378B2 (en) | 2008-12-05 | 2012-06-05 | Astellas Pharma Inc. | 2H-chromene compound and derivative thereof |
| ES2379242B1 (es) | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromeno. |
| CN103841969A (zh) * | 2011-08-04 | 2014-06-04 | 美国卫生和人力服务部 | 经由药物介导的对类二十烷酸平衡的操作治疗和预防微生物介导的疾病 |
| EP2693164A1 (en) | 2012-08-03 | 2014-02-05 | Universidad Politécnica de Madrid | Interferometric detection method |
| ES2534318B1 (es) | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
| ES2534336B1 (es) | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno como inhibidores de la interacción TCR-Nck |
| US9968604B2 (en) | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| CN104844471B (zh) * | 2015-04-21 | 2017-05-03 | 苏州远智医药科技有限公司 | 一种作为dor受体拮抗剂的化合物 |
| KR20260028873A (ko) | 2018-02-27 | 2026-03-04 | 아텍스 바이오파마 인코포레이티드 | Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체 |
-
2019
- 2019-02-27 KR KR1020267003633A patent/KR20260028873A/ko active Pending
- 2019-02-27 CN CN202311248809.1A patent/CN117304157A/zh active Pending
- 2019-02-27 WO PCT/US2019/019856 patent/WO2019169001A1/en not_active Ceased
- 2019-02-27 BR BR112020017386-0A patent/BR112020017386A2/pt unknown
- 2019-02-27 KR KR1020207027883A patent/KR102924679B1/ko active Active
- 2019-02-27 CA CA3091202A patent/CA3091202A1/en active Pending
- 2019-02-27 EP EP19710272.6A patent/EP3759086A1/en active Pending
- 2019-02-27 EA EA202091742A patent/EA202091742A1/ru unknown
- 2019-02-27 CN CN201980020981.7A patent/CN112189009B/zh active Active
- 2019-02-27 MX MX2020008814A patent/MX2020008814A/es unknown
- 2019-02-27 AU AU2019229258A patent/AU2019229258B2/en active Active
- 2019-02-27 SG SG11202008067QA patent/SG11202008067QA/en unknown
- 2019-02-27 US US16/287,771 patent/US10696663B2/en active Active
- 2019-02-27 IL IL301120A patent/IL301120B2/en unknown
- 2019-02-27 JP JP2020544852A patent/JP7317032B2/ja active Active
-
2020
- 2020-05-20 US US16/878,842 patent/US11008310B2/en active Active
- 2020-08-20 PH PH12020500638A patent/PH12020500638A1/en unknown
- 2020-08-24 IL IL276887A patent/IL276887B2/en unknown
- 2020-08-24 MX MX2023005716A patent/MX2023005716A/es unknown
- 2020-08-26 CO CONC2020/0010537A patent/CO2020010537A2/es unknown
-
2021
- 2021-04-26 US US17/240,041 patent/US11807633B2/en active Active
-
2023
- 2023-06-12 JP JP2023096315A patent/JP7521070B2/ja active Active
- 2023-09-21 US US18/471,594 patent/US12319675B2/en active Active
- 2023-11-24 ZA ZA2023/10843A patent/ZA202310843B/en unknown
- 2023-12-12 AU AU2023282201A patent/AU2023282201B2/en active Active
-
2024
- 2024-07-10 JP JP2024111017A patent/JP2024138421A/ja active Pending
-
2025
- 2025-05-01 US US19/196,040 patent/US20250346586A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023110094A5 (https=) | ||
| JP2021514007A5 (https=) | ||
| Scherman et al. | Olefin metathesis and quadruple hydrogen bonding: A powerful combination in multistep supramolecular synthesis | |
| IL276887B2 (en) | Novel chromium as inhibitors of tcr–nck interaction | |
| Petro et al. | Microwave Absorption and Molecular Structure in Liquids. XX. Dielectric Relaxation Times and Molecular Shapes of Some Substituted Benzenes and Pyridines1-3 | |
| JP2005515258A5 (https=) | ||
| Jia et al. | Insights into intermolecular interactions of spironolactone solvates | |
| DE68918877T2 (de) | Verfahren zur Herstellung von cyclischen Polydiorganosiloxanen durch Equilibrierung in der Gasphase. | |
| KR930023364A (ko) | 비페닐메틸-치환 피리돈 | |
| DE69105279T2 (de) | Polymere filme für nichtlineare optik der zweiten ordnung. | |
| Koizumi et al. | Crystallization technique of high-quality protein crystals controlling surface free energy | |
| JPWO2019169001A5 (https=) | ||
| JPH0610194B2 (ja) | ビオロゲン誘導体及びその製造方法 | |
| Volodin et al. | Organoelement compounds crystallized in situ: weak intermolecular interactions and lattice energies | |
| Fouda et al. | Discovery, synthesis, and in vitro characterization of 2, 3 derivatives of 4, 5, 6, 7-tetrahydro-benzothiophene as potent modulators of retinoic acid receptor-related orphan receptor γt | |
| PT1881972E (pt) | Processo para a produção de carbonato de vinileno | |
| Xu et al. | Stepwise Conversion of a Platinum Dimethyl Complex to a Perfluorometallacyclobutane Derivative | |
| Fisher et al. | Stibathiolanes: synthesis, solid-state structure, and solution behavior | |
| Paquette et al. | Conformational and stereochemical consequences of uniparticulate electrophilic additions to cis-bicyclo [6.1. 0] nonatrienes. Reactions with tetracyanoethylene | |
| JPH05214078A (ja) | プロペランを含むコポリマー及びそれより製造されるコンタクトレンズ | |
| Chang et al. | Crystal and molecular structure of bis (pyridine-2-carboxamido) nickel (II) dihydrate | |
| Matsumoto et al. | Synthesis of Iodinated Thiazolo [2, 3-a] isoquinolinium salts and their Crystal Structures with/without Halogen Bond | |
| JPH024722A (ja) | 弗素含有環状オレフィン化合物及びその製法 | |
| Capek et al. | On acrylonitrile polymerization in the presence of zinc salts | |
| Prest | Surface modification and controlled assembly of molecular materials |